Jazz, Concert Pharma sign license deal for narcolepsy drug development
Under the agreement, Jazz will develop Concert’s deuterium-modified sodium oxybate (D-SXB) compounds, including C-10323, and will have worldwide commercial rights to C-10323 as well as principal responsibility for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.